Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: J Pharmacol Toxicol Methods. 2012 Feb 26;65(2):64–74. doi: 10.1016/j.vascn.2012.02.002

Fig. 7.

Fig. 7

(a) Plot of the ratio of AUC for digoxin in the presence and absence of drug (inhibitor) vs. the ratio of peak plasma concentration of drug (inhibitor) and the IC50 for Fl-t-pgp. (b) Plot of the ratio of AUC for digoxin in the presence and absence of drug (inhibitor) vs. the ratio of gastrointestinal concentration of drug (inhibitor) and the IC50 for Fl-t-pgp. (c) Plot of the ratio of Cmax for digoxin in the presence and absence of drug (inhibitor) vs. the ratio of peak plasma concentration of drug (inhibitor) and the IC50 for Fl-t-pgp. (d) Plot of the ratio of Cmax for digoxin in the presence and absence of drug (inhibitor) vs. the ratio of gastrointestinal concentration of drug (inhibitor) and the IC50 for Fl-t-pgp. In vivo data are taken from Fenner et al. (Fenner et al., 2009).